Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers

27 Jan 2021

Abstract excerpt

Cells are continuously subjected to DNA damaging agents. DNA damages are repaired by one of the many pathways guarding genomic integrity. When one or several DNA damage pathways are rendered inefficient, cells can accumulate mutations, which modify normal cellular pathways, favoring abnormal cell growth. This supports malignant transformation, which can occur when cells acquire resistance to cell cycle...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33516088
DOI: 10.1016/j.tranon.2021.101012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancersPMID 33516088Read ↗

Clinical approaches to overcome PARP inhibitor resistanceSemantic proximity Read ↗

PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review.Semantic proximity Read ↗

Strategies for the prevention or reversal of PARP inhibitor resistance.Semantic proximity Read ↗

Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatmentSemantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP InhibitorsSemantic proximity Read ↗

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast CancersSemantic proximity Read ↗

PARP Inhibitors in Breast and Ovarian CancerSemantic proximity Read ↗

Insights into the Possible Molecular Mechanisms of Resistance to PARP InhibitorsSemantic proximity Read ↗

Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated CancerSemantic proximity Read ↗

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistanceSemantic proximity Read ↗

Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP InhibitorsSemantic proximity Read ↗

Therapeutic targeting and patient selection for cancers with homologous recombination defects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.